Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Extranodal NK-T-Cell × Ice × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

pegaspargase 3 tislelizumab 1 sugemalimab 1 relatlimab 1 gemcitabine-oxaliplatin regimen 1 Vorinostat 1 Valganciclovir 1 Therapeutics 1 Polymerase Chain Reaction 1 Oxaliplatin 1 Nivolumab 1 Immune Checkpoint Inhibitors 1 Ice 1 Gemcitabine 1 Ganciclovir 1 Foscarnet 1 Flow Cytometry 1 Cholecalciferol 1 Azacitidine 1 Antiviral Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡